FDG 기반 PET/CT 스캔: 종양 대사의 비침습적 영상화를 위한 방사선 추적자 사용 방법

Executive Industry Relevance

Non-invasive FDG PET/CT imaging enables quantitative assessment of tumor metabolic activity, supporting early-stage oncology target validation and mechanistic de-risking. This approach provides translational continuity from preclinical models to clinical imaging, enhancing predictive confidence in metabolic pathway targeting. Integration of standardized imaging protocols strengthens portfolio decision-making by enabling reproducible, quantitative readouts across discovery and preclinical phases.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Quantitative imaging of glycolytic activity enables functional validation of metabolic targets in oncology models.
• Non-invasive readouts support mechanistic de-risking and clarify pathway engagement in vivo.
• Standardized imaging protocols facilitate predictive confidence and triage of metabolic hypotheses.

Screening & Assay Development

• Validated PET/CT imaging systems provide reproducible, quantitative outputs for compound evaluation.
• Standardization of animal handling and tracer administration ensures assay reliability and comparability.
• Quantitative imaging readouts enable robust screening of metabolic modulators in disease-relevant models.

Translational & Preclinical Research

• Alignment of preclinical imaging with clinical PET/CT endpoints supports translational biomarker development.
• Quantitative metabolic imaging informs risk-adjusted advancement decisions for metabolic pathway inhibitors.
• Continuity of imaging protocols across models enhances translational relevance and predictive value.

Pipeline & Workflow Integration

FDG PET/CT imaging bridges early discovery, lead identification, and preclinical validation by providing standardized, quantitative metabolic readouts in vivo.

• Discovery Biology: Enables hypothesis testing and pathway clarification through non-invasive metabolic imaging.
• Screening: Supports assay readiness and reproducibility with quantitative PET/CT outputs.
• Analytics: Provides standardized measurements of radiotracer uptake for condition comparison.
• Translational Research: Aligns preclinical imaging endpoints with clinical biomarker strategies.
• Enterprise Reuse: Establishes a reusable imaging platform for diverse oncology and metabolic research programs.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence and target validation by quantifying tumor metabolism in vivo.
• Operational Value: Delivers standardized, reproducible imaging workflows for cross-study comparability.
• Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk through robust metabolic readouts.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of metabolic pathway programs.

Implementation Considerations

• Requires expertise in radiotracer handling, animal anesthesia, and PET/CT instrumentation.
• Demands access to dose calibrators, imaging chambers, and regulatory-compliant facilities.
• Standardization of animal preparation and tracer administration is critical for reproducibility.
• Protocols must be adapted for different tumor models and metabolic contexts as needed.
• Strict adherence to radiation safety and institutional guidelines is mandatory.

Biopharma FAQs